Earnings Scheduled For March 27, 2024
Companies Reporting Before The Bell
• Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.
Gamida Cell Earnings Preview
Gamida Cell (NASDAQ:GMDA) is set to give its latest quarterly earnings report on Wednesday, 2024-03-27. Here’s what investors…
Expert Ratings for Gamida Cell
Over the past 3 months, 4 analysts have published their opinion on Gamida Cell (NASDAQ:GMDA) stock. These analysts…
Small-Caps Grossly Underperform Broader Market Amid This Red Flag: 5 Stocks On The Scanner
Small-cap stocks have not taken off significantly this year despite the broader market rebound, primarily due to their increasing debt burden, a report says.
Why Beyond Air Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Shares of Beyond Air, Inc. (NASDAQ: XAIR) dipped during Tuesday’s session following weak quarterly results.
Earnings Scheduled For November 14, 2023
Companies Reporting Before The Bell
• CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million.
Gamida Cell’s Blood Cancer Candidate Shows Encouraging Anti-Tumor Activity In Heavily Pretreated Patients
Gamida Cell Ltd (NASDAQ: GMDA) released new early data in 10 patients with CD20-positive non-Hodgkin lymphoma enrolled in the first three cohorts in an ongoing Phase 1 study of natural killer (NK)
Gamida Cell Reports Preliminary Data From Phase 1 Study Of Natural Killer Cell Therapy Candidate GDA-201
Data show promising early evidence of anti-tumor activity in patients with relapsed/refractory B cell non-Hodgkin lymphomaFull data readout of Phase 1 study expected in Q1 2024Gamida Cell Ltd. (NASDAQ:GMDA), a cell
Gamida Cell Issues Update On Israel Operations
Gamida Cell Ltd. (NASDAQ:GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today issued an update on its operations in Israel."We remain profoundly saddened by the attacks in Israel this
Gamida Cell Ltd. Announces That The First Patient Has Received A Stem Cell Transplant With Omisirge
Omisirge is the only allogeneic stem cell therapy approved by the U.S. Food and Drug Administration (FDA) on the basis of a global randomized Phase 3 trialRapid onboarding of transplant centers and significant payer